Atara Biotherapeutics (ATRA) Common Equity (2013 - 2026)

Atara Biotherapeutics has reported Common Equity for 14 years, with the latest figure at -$37.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 32.25% year-over-year to -$37.3 million; the trailing twelve-month figure through Mar 2026 stood at -$37.3 million (up 32.25% YoY), and the FY2025 full-year result was -$38.5 million, up 60.42% from the prior year.
• Common Equity for Q1 2026 stood at -$37.3 million, up from -$38.5 million in the prior quarter.
• The five-year high for Common Equity was $257.5 million in Q2 2022, with the low at -$110.9 million in Q2 2024.
• Historically, Common Equity has averaged $18.6 million across 5 years, with a median of -$36.6 million in 2025.
• Annual changes were most pronounced in 2024 — Common Equity sank 1587.36% — and 2025, when it surged 68.39%.
• Atara Biotherapeutics' Common Equity stood at $126.6 million in 2022, then fell by 21.64% to $99.2 million in 2023, then plunged by 198.04% to -$97.3 million in 2024, then surged by 60.42% to -$38.5 million in 2025, then grew by 3.09% to -$37.3 million in 2026.
• The last three Common Equity figures came in at -$37.3 million (Q1 2026), -$38.5 million (Q4 2025), and -$36.6 million (Q3 2025), per Business Quant data.